aldosterone has been researched along with Diabetic Nephropathies in 117 studies
Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Prostasin was measured in plasma and urine from type 2 diabetic patients with resistant hypertension (n = 112) randomized to spironolactone/placebo in a clinical trial." | 9.24 | Albuminuria is associated with an increased prostasin in urine while aldosterone has no direct effect on urine and kidney tissue abundance of prostasin. ( Bistrup, C; Hansen, MR; Hansen, PB; Hinrichs, GR; Jacobsen, IA; Jensen, BL; Kurt, B; Oxlund, C; Schwarzensteiner, I; Stæhr, M; Svenningsen, P; Thuesen, AD; Toft, A, 2017) |
| " In this study, we conducted an open-label and randomized trial to compare the effects of benidipine with those of amlodipine on blood pressure (BP), albuminuria and aldosterone concentration in hypertensive patients with mild-to-moderate stage chronic kidney disease (CKD)." | 9.15 | Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. ( Abe, M; Fujita, T; Maruyama, N; Maruyama, T; Matsumoto, K; Matsumoto, S; Okada, K; Soma, M, 2011) |
| "Forty type 2 diabetic patients with hypertension and nephropathy receiving angiotensin receptor II blockers were enrolled and randomly divided into two groups: the efonidipine group was administered efonidipine hydrochloride ethanolate 40 mg/day and the amlodipine group was admin-istered amlodipine besilate 5 mg/day for 12 months." | 9.14 | Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy. ( Ban, N; Endo, K; Kawana, H; Miyashita, Y; Nagayama, D; Ohhira, M; Oyama, T; Saiki, A; Sasaki, H; Shirai, K; Yamaguchi, T, 2009) |
| "In this study we evaluated the effect of a dual blockade with enalapril and losartan on the reduction of overt macroproteinuria and its potential mechanism(s) in hypertensive patients with type 2 diabetes." | 9.12 | Dual blockade of angiotensin II with enalapril and losartan reduces proteinuria in hypertensive patients with type 2 diabetes. ( Hirata, A; Igarashi, M; Kadomoto, Y; Tominaga, M, 2006) |
| " The authors hypothesized that reduction in aldosterone production in diabetes by amlodipine or aliskiren improves diabetic kidney disease by attenuating renal oxidative stress and fibrosis." | 7.79 | Reduction of aldosterone production improves renal oxidative stress and fibrosis in diabetic rats. ( Matavelli, LC; Siragy, HM, 2013) |
| "Aldosterone has emerged as a deleterious hormone in the kidney, for example as a potent inducer of proteinuria." | 6.47 | Endocrinological aspects of proteinuria and podocytopathy in diabetes: role of the aldosterone/mineralocorticoid receptor system. ( Fujita, T; Nagase, M, 2011) |
| "Aldosterone is a mediator of progressive renal disease, but the mechanisms for aldosterone-mediated renal impairment in mice with diabetes are not fully defined." | 5.56 | miR-196b-5p-enriched extracellular vesicles from tubular epithelial cells mediated aldosterone-induced renal fibrosis in mice with diabetes. ( Gao, R; Ge, Q; Hu, J; Hu, R; Li, Q; Li, X; Luo, T; Ma, L; Peng, C; Qing, H; Wang, Y; Wang, Z; Wu, C; Xiao, X; Yang, J; Yang, S; Young, MJ, 2020) |
| "Considering the role of aldosterone in diabetic nephropathy, genetic polymorphism of this gene may contribute to the development and progression of diabetic nephropathy." | 5.35 | Polymorphism of the aldosterone synthase gene is not associated with progression of diabetic nephropathy, but associated with hypertension in type 2 diabetic patients. ( Cha, DR; Kang, YS; Kim, HK; Ko, GJ; Lee, MH; Song, HK, 2008) |
| " Prostasin was measured in plasma and urine from type 2 diabetic patients with resistant hypertension (n = 112) randomized to spironolactone/placebo in a clinical trial." | 5.24 | Albuminuria is associated with an increased prostasin in urine while aldosterone has no direct effect on urine and kidney tissue abundance of prostasin. ( Bistrup, C; Hansen, MR; Hansen, PB; Hinrichs, GR; Jacobsen, IA; Jensen, BL; Kurt, B; Oxlund, C; Schwarzensteiner, I; Stæhr, M; Svenningsen, P; Thuesen, AD; Toft, A, 2017) |
| "Spironolactone reduced albuminuria along with conventional RAS inhibitors in patients with diabetic nephropathy." | 5.20 | Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial. ( Ando, M; Araki, H; Goto, M; Imai, E; Kanasaki, K; Kato, S; Kobori, H; Koya, D; Makino, H; Maruyama, S; Matsuo, S; Nishiyama, A; Ogawa, D; Oiso, Y; Uzu, T; Wada, J, 2015) |
| "We aimed to assess the effect of aliskiren treatment on blood pressure, albuminuria, and kidney function in patients with chronic kidney disease (CKD)." | 5.17 | Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease. ( Abe, M; Baba, S; Inoshita, A; Maruyama, N; Okada, K; Soma, M; Suzuki, H; Takashima, H, 2013) |
| " In this study, we conducted an open-label and randomized trial to compare the effects of benidipine with those of amlodipine on blood pressure (BP), albuminuria and aldosterone concentration in hypertensive patients with mild-to-moderate stage chronic kidney disease (CKD)." | 5.15 | Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. ( Abe, M; Fujita, T; Maruyama, N; Maruyama, T; Matsumoto, K; Matsumoto, S; Okada, K; Soma, M, 2011) |
| "Forty type 2 diabetic patients with hypertension and nephropathy receiving angiotensin receptor II blockers were enrolled and randomly divided into two groups: the efonidipine group was administered efonidipine hydrochloride ethanolate 40 mg/day and the amlodipine group was admin-istered amlodipine besilate 5 mg/day for 12 months." | 5.14 | Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy. ( Ban, N; Endo, K; Kawana, H; Miyashita, Y; Nagayama, D; Ohhira, M; Oyama, T; Saiki, A; Sasaki, H; Shirai, K; Yamaguchi, T, 2009) |
| "In this study we evaluated the effect of a dual blockade with enalapril and losartan on the reduction of overt macroproteinuria and its potential mechanism(s) in hypertensive patients with type 2 diabetes." | 5.12 | Dual blockade of angiotensin II with enalapril and losartan reduces proteinuria in hypertensive patients with type 2 diabetes. ( Hirata, A; Igarashi, M; Kadomoto, Y; Tominaga, M, 2006) |
| " The authors hypothesized that reduction in aldosterone production in diabetes by amlodipine or aliskiren improves diabetic kidney disease by attenuating renal oxidative stress and fibrosis." | 3.79 | Reduction of aldosterone production improves renal oxidative stress and fibrosis in diabetic rats. ( Matavelli, LC; Siragy, HM, 2013) |
| "Aldosterone breakthrough is a frequent event 1 year after initiating renin-angiotensin-aldosterone system blockade, particularly in participants exposed to intensive lowering of BP with sodium depletion and short-acting angiotensin II receptor blockers." | 2.78 | Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy. ( Bakris, G; Esnault, VL; Fafin, C; Favre, G; Moranne, O; Pradier, C, 2013) |
| "In the AVOID study, 599 patients with type 2 diabetes, hypertension and nephropathy received 6 months aliskiren (150 mg force titrated to 300 mg once daily after 3 months) or placebo added to losartan 100 mg and optimal antihypertensive therapy." | 2.77 | Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy. ( Hans-Henrik, P; Hollenberg, NK; Lewis, EJ; Lewis, JB; Persson, F; Rossing, P, 2012) |
| "Aldosterone is an important pathogenetic factor, independent of the renin-angiotensin system in cardiovascular and renal disease." | 2.73 | Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. ( Karashima, S; Oda, N; Takata, H; Takeda, Y; Usukura, M; Yamagishi, M; Yamamoto, Y; Yoneda, T, 2007) |
| "Ultrahigh dosing of irbesartan (900 mg once daily) is generally safe and offers additional renoprotection independent of changes in systemic blood pressure and GFR in comparison to the currently recommended dose of 300 mg." | 2.71 | Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. ( Boomsma, F; Jensen, BR; Parving, HH; Rossing, K; Schjoedt, KJ, 2005) |
| "On spironolactone treatment, one patient was excluded due to hyperkalemia (plasma potassium 5." | 2.71 | Beneficial impact of spironolactone in diabetic nephropathy. ( Boomsma, F; Juhl, TR; Parving, HH; Rossing, K; Rossing, P; Schjoedt, KJ; Tarnow, L, 2005) |
| "However, in patients with type 2 diabetes, both with normoalbuminuria and microalbuminuria, RI values after the test were significantly lower than baseline values (P < 0." | 2.71 | Intrarenal hemodynamic changes after captopril test in patients with type 2 diabetes: a duplex Doppler sonography study. ( Emoto, M; Hosoi, M; Inaba, M; Ishimura, E; Kawagishi, T; Matsumoto, N; Nakatani, T; Nishizawa, Y; Shoji, S; Shoji, T; Taniwaki, H, 2003) |
| "It has been reported that continuous ACE inhibitor therapy does not necessarily produce a maintained decrease in plasma aldosterone levels, which may remain high or increase eventually during long-term use (aldosterone escape)." | 2.71 | Effectiveness of aldosterone blockade in patients with diabetic nephropathy. ( Hayashi, K; Naruse, M; Saruta, T; Sato, A, 2003) |
| "Early stage of diabetic nephropathy does not influence the examined hormones level." | 2.68 | [Activity of the renin-angiotensin-aldosterone system in euglycemic type I diabetic patients on intensive insulin treatment without diabetic neuropathy]. ( Górska, J; Grzeszczak, W; Krywult, D; Lacka, B; Morawin, E; Strojek, K, 1995) |
| "In conclusion, in this study of IDDM patients with nephropathy and high normal or mildly hypertensive blood pressure, a difference in sodium intake of about 100 mmol/day for a period of 4 weeks led to a slight reduction of clinic diastolic blood pressure." | 2.68 | Effects of dietary sodium on blood pressure in IDDM patients with nephropathy. ( Bender, R; Berger, M; Dworschak, A; Mühlhauser, I; Prange, K; Sawicki, PT; Schaden, W, 1996) |
| "Diabetic kidney disease is a growing problem leading to end-stage kidney disease but also atherosclerotic cardiovascular disease and heart failure." | 2.66 | Mitigating risk of aldosterone in diabetic kidney disease. ( Frimodt-Møller, M; Persson, F; Rossing, P, 2020) |
| "Aldosterone has emerged as a deleterious hormone in the kidney, for example as a potent inducer of proteinuria." | 2.47 | Endocrinological aspects of proteinuria and podocytopathy in diabetes: role of the aldosterone/mineralocorticoid receptor system. ( Fujita, T; Nagase, M, 2011) |
| "Aliskiren is a new renin inhibitor that block the RAAS at its origin." | 2.45 | Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity. ( Dalla Vestra, M; Masiero, A; Simioni, N, 2009) |
| "Aldosterone plays an important role in salt and water homeostasis and blood pressure control through the classical mineralocorticoid receptor." | 2.45 | Aldosterone and diabetic kidney disease. ( Cha, DR; Kang, YS, 2009) |
| "Hypertension is often associated clinically with diabetes as part of the insulin-resistance syndrome or as a manifestation of renal disease." | 2.43 | Hypertension and diabetes: role of the renin-angiotensin system. ( Cooper, ME; Jandeleit-Dahm, K, 2006) |
| "Idiopathic nodular glomerulosclerosis has a poor renal prognosis and is characterized by diffuse nodular glomerulosclerotic lesions in the absence of diabetic mellitus." | 1.91 | A case of idiopathic nodular glomerulosclerosis successfully treated by intensive blockade of the renin-angiotensin-aldosterone system. ( Arakawa, M; Hosojima, M; Ito, Y; Kabasawa, H; Narita, I; Saito, A; Suzuki, Y; Yamaguchi, H, 2023) |
| "Aldosterone has been assumed to be one of aggravating factors in diabetic kidney disease (DKD)." | 1.91 | Sacubitril/valsartan ameliorates renal tubulointerstitial injury through increasing renal plasma flow in a mouse model of type 2 diabetes with aldosterone excess. ( Handa, T; Ikushima, A; Inoue, Y; Ishii, A; Ishimura, T; Kato, Y; Minamino, N; Mori, KP; Mukoyama, M; Nishio, H; Ohno, S; Sugioka, S; Yamada, H; Yanagita, M; Yokoi, H, 2023) |
| "In patients with diabetic kidney disease alternative MR activation is conceivable as cortisol and cortisone metabolites are increased." | 1.72 | Increased glucocorticoid metabolism in diabetic kidney disease. ( Ackermann, D; Bochud, M; Burnier, M; Dick, B; Ehret, G; Gennari-Moser, C; Guessous, I; Jamin, H; Klossner, R; Martin, PY; Mohaupt, MG; Paccaud, F; Pechère-Bertschi, A; Ponte, B; Pruijm, M; Vogt, B, 2022) |
| "Cell treatment by aldosterone+glycated albumin increased intracellular MGO, MR and RAGE expression; hampered antioxidant, detoxification enzyme activities and reduced NRF-2, Keap-1 expression." | 1.72 | Mineralocorticoid interaction with glycated albumin downregulates NRF - 2 signaling pathway in renal cells: Insights into diabetic nephropathy. ( Apte, MM; Bangar, NS; Gaikwad, DD; Gvalani, A; Tupe, RS, 2022) |
| "Aldosterone is a mediator of progressive renal disease, but the mechanisms for aldosterone-mediated renal impairment in mice with diabetes are not fully defined." | 1.56 | miR-196b-5p-enriched extracellular vesicles from tubular epithelial cells mediated aldosterone-induced renal fibrosis in mice with diabetes. ( Gao, R; Ge, Q; Hu, J; Hu, R; Li, Q; Li, X; Luo, T; Ma, L; Peng, C; Qing, H; Wang, Y; Wang, Z; Wu, C; Xiao, X; Yang, J; Yang, S; Young, MJ, 2020) |
| "After treatment, hyperglycemia and urine microalbumin levels were attenuated in both OL-DA and OL-VO rather than in the OL-C group (P < 0." | 1.43 | Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes. ( Ahn, YB; Chung, S; Kim, ES; Kim, JW; Kim, MJ; Kim, SJ; Ko, SH; Lee, EM; Moon, SD; Shin, SJ; Yoo, YH, 2016) |
| "Diabetic nephropathy was defined as macroalbuminuria or end-stage renal disease (dialysis or renal transplant)." | 1.40 | Renin-angiotensin-aldosterone-blockade is associated with decreased use of antidepressant therapy in patients with type 1 diabetes and diabetic nephropathy. ( Ahola, AJ; Forsblom, C; Groop, PH; Harjutsalo, V, 2014) |
| "sPRR in patients with primary aldosteronism (low renin-low prorenin) and Gitelman syndrome (high renin-high prorenin) were similar and ≈10% higher than in healthy subjects." | 1.40 | Plasma soluble (pro)renin receptor is independent of plasma renin, prorenin, and aldosterone concentrations but is affected by ethnicity. ( Azizi, M; Baron, S; Bergerot, D; Blanchard, A; Caumont-Prim, A; Chambon, Y; Curis, E; Frank, M; Hirose, T; Nguyen, G; Tabard, SB; Totsune, K, 2014) |
| "Diabetic nephropathy is characterized by elevated macrophage infiltration and inflammation." | 1.40 | Hemin therapy improves kidney function in male streptozotocin-induced diabetic rats: role of the heme oxygenase/atrial natriuretic peptide/adiponectin axis. ( Jadhav, A; Ndisang, JF, 2014) |
| "Spironolactone can inhibit high glucose-induced renal tubular epithelial cells EMT, which may be an important mechanism for the inhibition of renal interstitial fibrosis." | 1.36 | [Effect of aldosterone and its antagonist spironolactone on epithelial-mesenchymal transition of normal rat kidney epithelial cells in high glucose]. ( Ao, X; Hong, X; Liu, K; Pouranan, V; Xiao, Z; Yuan, M; Zhou, Q, 2010) |
| "Considering the role of aldosterone in diabetic nephropathy, genetic polymorphism of this gene may contribute to the development and progression of diabetic nephropathy." | 1.35 | Polymorphism of the aldosterone synthase gene is not associated with progression of diabetic nephropathy, but associated with hypertension in type 2 diabetic patients. ( Cha, DR; Kang, YS; Kim, HK; Ko, GJ; Lee, MH; Song, HK, 2008) |
| "The correlation between aldosterone and diabetic nephropathy suggests a clinical relevance of this observation." | 1.35 | Increased aldosterone levels in a model of type 2 diabetes mellitus. ( Birner, C; Endemann, DH; Fredersdorf, S; Heitzmann, D; Luchner, A; Muders, F; Resch, M; Riegger, GA; Schmid, P; Stoelcker, B; Ulucan, C; Weil, J, 2009) |
| "Spironolactone treatment did not induce any significant change in blood glucose levels and blood pressure." | 1.33 | Role of aldosterone in diabetic nephropathy. ( Cha, DR; Han, JY; Han, KH; Han, SY; Jee, YH; Kang, YS; Kim, HK; Kim, YS, 2005) |
| "Spironolactone treatment did not induce any significant differences in body weight, kidney/body weight ratio, serum creatinine concentration, blood glucose levels, or systolic blood pressure." | 1.33 | Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. ( Cha, DR; Han, JY; Han, KH; Han, SY; Jee, YH; Kang, YS; Kim, HK; Kim, YS; Lee, MH, 2006) |
| "RFR was examined in 33 IDDM patients in similar glycaemic and metabolic control and compared to 12 healthy control subjects, during eight 1 h clearance periods prior to, during and after a 3-h stimulation by amino acid infusion (4." | 1.30 | Renal functional reserve in IDDM patients. ( Ader, JL; Hanaire-Broutin, H; Sackmann, H; Tack, I; Tauber, JP; Tran-Van, T, 1998) |
| "Presence of moderately advanced diabetic nephropathy and autonomic neuropathy influenced only slightly WI induced alterations of the renin-aldosterone system and AVP secretion." | 1.27 | [Effect of water immersion on plasma renin activity, vasopressin and aldosterone level in diabetics]. ( Duława, J; Grzeszczak, W; Kokot, F; Wiecek, A, 1987) |
| "Low PRA in diabetic nephropathy with slightly to moderately impaired renal function may not be due to hyaline destruction of the arteriolar walls, but to other factors such as sympathetic nervous dysfunction." | 1.26 | Renin-angiotensin-aldosterone system in mild diabetic nephropathy. ( Ideura, T; Matsuda, O; Shiigai, T; Takeuchi, J; Tomita, K, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (17.95) | 18.7374 |
| 1990's | 8 (6.84) | 18.2507 |
| 2000's | 40 (34.19) | 29.6817 |
| 2010's | 37 (31.62) | 24.3611 |
| 2020's | 11 (9.40) | 2.80 |
| Authors | Studies |
|---|---|
| Higa, M | 1 |
| Ichijo, T | 1 |
| Hirose, T | 2 |
| Ackermann, D | 1 |
| Vogt, B | 1 |
| Bochud, M | 1 |
| Burnier, M | 1 |
| Martin, PY | 1 |
| Paccaud, F | 1 |
| Ehret, G | 1 |
| Guessous, I | 1 |
| Ponte, B | 1 |
| Pruijm, M | 1 |
| Pechère-Bertschi, A | 1 |
| Jamin, H | 1 |
| Klossner, R | 1 |
| Dick, B | 1 |
| Mohaupt, MG | 1 |
| Gennari-Moser, C | 1 |
| Gaikwad, DD | 1 |
| Bangar, NS | 1 |
| Apte, MM | 1 |
| Gvalani, A | 1 |
| Tupe, RS | 1 |
| Okuda, Y | 1 |
| Ito, S | 2 |
| Kashihara, N | 1 |
| Shikata, K | 1 |
| Nangaku, M | 1 |
| Wada, T | 1 |
| Sawanobori, T | 1 |
| Taguri, M | 1 |
| Yamaguchi, H | 1 |
| Hosojima, M | 1 |
| Kabasawa, H | 1 |
| Ito, Y | 1 |
| Suzuki, Y | 1 |
| Saito, A | 1 |
| Arakawa, M | 1 |
| Narita, I | 1 |
| Mende, CW | 1 |
| Samarakoon, R | 1 |
| Higgins, PJ | 1 |
| Nishio, H | 1 |
| Ishii, A | 1 |
| Yamada, H | 1 |
| Mori, KP | 1 |
| Kato, Y | 1 |
| Ohno, S | 1 |
| Handa, T | 1 |
| Sugioka, S | 1 |
| Ishimura, T | 1 |
| Ikushima, A | 1 |
| Inoue, Y | 1 |
| Minamino, N | 1 |
| Mukoyama, M | 1 |
| Yanagita, M | 1 |
| Yokoi, H | 1 |
| Frimodt-Møller, M | 1 |
| Persson, F | 2 |
| Rossing, P | 4 |
| Hu, R | 1 |
| Li, X | 1 |
| Peng, C | 1 |
| Gao, R | 1 |
| Ma, L | 1 |
| Hu, J | 1 |
| Luo, T | 1 |
| Qing, H | 1 |
| Wang, Y | 1 |
| Ge, Q | 1 |
| Wang, Z | 1 |
| Wu, C | 1 |
| Xiao, X | 1 |
| Yang, J | 1 |
| Young, MJ | 1 |
| Li, Q | 1 |
| Yang, S | 1 |
| Mabuza, LP | 1 |
| Gamede, MW | 1 |
| Maikoo, S | 1 |
| Booysen, IN | 1 |
| Ngubane, PS | 1 |
| Khathi, A | 1 |
| Sydorchuk, L | 1 |
| Dzhuryak, V | 1 |
| Sydorchuk, A | 1 |
| Levytska, S | 1 |
| Petrynych, V | 1 |
| Knut, R | 1 |
| Kshanovska, A | 1 |
| Iftoda, O | 1 |
| Tkachuk, O | 1 |
| Kyfiak, P | 1 |
| Popovich, A | 1 |
| Khomko, O | 1 |
| Sydorchuk, R | 1 |
| Lytvyn, Y | 1 |
| Godoy, LC | 1 |
| Scholtes, RA | 1 |
| van Raalte, DH | 1 |
| Cherney, DZ | 1 |
| Dong, D | 1 |
| Fan, TT | 1 |
| Ji, YS | 1 |
| Yu, JY | 1 |
| Wu, S | 1 |
| Zhang, L | 1 |
| Ocello, A | 1 |
| La Rosa, S | 1 |
| Fiorini, F | 1 |
| Randone, S | 1 |
| Maccarrone, R | 1 |
| Battaglia, G | 1 |
| Granata, A | 1 |
| Moranne, O | 1 |
| Bakris, G | 1 |
| Fafin, C | 1 |
| Favre, G | 1 |
| Pradier, C | 1 |
| Esnault, VL | 1 |
| Navaneethan, SD | 1 |
| Bravo, EL | 1 |
| Fernández-Juárez, G | 1 |
| Luño, J | 1 |
| Barrio, V | 1 |
| de Vinuesa, SG | 1 |
| Praga, M | 1 |
| Goicoechea, M | 1 |
| Lahera, V | 1 |
| Casas, L | 1 |
| Oliva, J | 1 |
| Ndisang, JF | 1 |
| Jadhav, A | 1 |
| Nguyen, G | 1 |
| Blanchard, A | 1 |
| Curis, E | 1 |
| Bergerot, D | 1 |
| Chambon, Y | 1 |
| Caumont-Prim, A | 1 |
| Tabard, SB | 1 |
| Baron, S | 1 |
| Frank, M | 1 |
| Totsune, K | 1 |
| Azizi, M | 1 |
| Van Buren, PN | 1 |
| Adams-Huet, B | 1 |
| Nguyen, M | 1 |
| Molina, C | 1 |
| Toto, RD | 1 |
| Ahola, AJ | 1 |
| Harjutsalo, V | 1 |
| Forsblom, C | 1 |
| Groop, PH | 1 |
| Abe, M | 5 |
| Oikawa, O | 1 |
| Okada, K | 5 |
| Soma, M | 5 |
| Kato, S | 1 |
| Maruyama, S | 1 |
| Makino, H | 1 |
| Wada, J | 1 |
| Ogawa, D | 1 |
| Uzu, T | 1 |
| Araki, H | 1 |
| Koya, D | 1 |
| Kanasaki, K | 1 |
| Oiso, Y | 1 |
| Goto, M | 1 |
| Nishiyama, A | 1 |
| Kobori, H | 1 |
| Imai, E | 1 |
| Ando, M | 1 |
| Matsuo, S | 2 |
| Luther, JM | 1 |
| Yang, P | 1 |
| Huang, T | 1 |
| Xu, G | 1 |
| Shin, SJ | 1 |
| Chung, S | 1 |
| Kim, SJ | 1 |
| Lee, EM | 1 |
| Yoo, YH | 1 |
| Kim, JW | 1 |
| Ahn, YB | 1 |
| Kim, ES | 1 |
| Moon, SD | 1 |
| Kim, MJ | 1 |
| Ko, SH | 1 |
| Oxlund, C | 1 |
| Kurt, B | 1 |
| Schwarzensteiner, I | 1 |
| Hansen, MR | 1 |
| Stæhr, M | 1 |
| Svenningsen, P | 1 |
| Jacobsen, IA | 1 |
| Hansen, PB | 1 |
| Thuesen, AD | 1 |
| Toft, A | 1 |
| Hinrichs, GR | 1 |
| Bistrup, C | 1 |
| Jensen, BL | 1 |
| Fredersdorf, S | 1 |
| Endemann, DH | 1 |
| Luchner, A | 1 |
| Heitzmann, D | 1 |
| Ulucan, C | 1 |
| Birner, C | 1 |
| Schmid, P | 1 |
| Stoelcker, B | 1 |
| Resch, M | 1 |
| Muders, F | 1 |
| Riegger, GA | 1 |
| Weil, J | 1 |
| Ko, GJ | 1 |
| Kang, YS | 4 |
| Lee, MH | 2 |
| Song, HK | 1 |
| Kim, HK | 3 |
| Cha, DR | 4 |
| Ackermann, TF | 1 |
| Boini, KM | 1 |
| Völkl, H | 1 |
| Bhandaru, M | 1 |
| Bareiss, PM | 1 |
| Just, L | 1 |
| Vallon, V | 2 |
| Amann, K | 1 |
| Kuhl, D | 1 |
| Feng, Y | 1 |
| Hammes, HP | 1 |
| Lang, F | 1 |
| Schroth, J | 1 |
| Satriano, J | 1 |
| Blantz, RC | 1 |
| Thomson, SC | 1 |
| Rieg, T | 1 |
| Hayashi, T | 1 |
| Takai, S | 1 |
| Yamashita, C | 1 |
| Takemitsu, T | 1 |
| Ichihara, A | 1 |
| Kaneshiro, Y | 1 |
| Sakoda, M | 1 |
| Kurauchi-Mito, A | 1 |
| Narita, T | 1 |
| Kinouchi, K | 1 |
| Yamashita, N | 1 |
| Itoh, H | 1 |
| Sasaki, H | 1 |
| Saiki, A | 1 |
| Endo, K | 1 |
| Ban, N | 1 |
| Yamaguchi, T | 1 |
| Kawana, H | 1 |
| Nagayama, D | 1 |
| Ohhira, M | 1 |
| Oyama, T | 1 |
| Miyashita, Y | 1 |
| Shirai, K | 1 |
| Rubin, MF | 1 |
| Townsend, RR | 1 |
| Kosugi, T | 1 |
| Heinig, M | 1 |
| Nakayama, T | 1 |
| Nakagawa, T | 2 |
| Dalla Vestra, M | 1 |
| Simioni, N | 1 |
| Masiero, A | 1 |
| Liu, K | 2 |
| Zhou, Q | 2 |
| Ao, X | 1 |
| Pouranan, V | 2 |
| Hong, X | 1 |
| Xiao, Z | 2 |
| Yuan, M | 2 |
| Pichler, RH | 1 |
| de Boer, IH | 1 |
| Toba, H | 1 |
| Mitani, T | 1 |
| Takahashi, T | 1 |
| Imai, N | 1 |
| Serizawa, R | 1 |
| Wang, J | 1 |
| Kobara, M | 1 |
| Nakata, T | 1 |
| Nishikawa, T | 1 |
| Matsuzawa, Y | 1 |
| Suematsu, S | 1 |
| Saito, J | 1 |
| Omura, M | 1 |
| Kino, T | 1 |
| Kujal, P | 1 |
| Chábová, VČ | 1 |
| Vernerová, Z | 1 |
| Walkowska, A | 1 |
| Kompanowska-Jezierska, E | 1 |
| Sadowski, J | 1 |
| Vaňourková, Z | 1 |
| Husková, Z | 1 |
| Opočenský, M | 1 |
| Skaroupková, P | 1 |
| Schejbalová, S | 1 |
| Kramer, HJ | 1 |
| Rakušan, D | 1 |
| Malý, J | 1 |
| Netuka, I | 1 |
| Vaněčková, I | 1 |
| Kopkan, L | 1 |
| Cervenka, L | 1 |
| Nagase, M | 1 |
| Fujita, T | 2 |
| Maruyama, N | 4 |
| Matsumoto, S | 2 |
| Maruyama, T | 1 |
| Matsumoto, K | 2 |
| Kristensen, KE | 1 |
| Egfjord, M | 1 |
| Hunter, JD | 1 |
| Ravert, PK | 1 |
| Lassetter, JH | 1 |
| Williams, M | 1 |
| Bertocchio, JP | 1 |
| Warnock, DG | 1 |
| Jaisser, F | 1 |
| Nobakht, N | 1 |
| Kamgar, M | 1 |
| Rastogi, A | 1 |
| Schrier, RW | 1 |
| Lewis, JB | 1 |
| Lewis, EJ | 1 |
| Hollenberg, NK | 1 |
| Hans-Henrik, P | 1 |
| Lian, M | 1 |
| Hewitson, TD | 1 |
| Wigg, B | 1 |
| Samuel, CS | 1 |
| Chow, F | 1 |
| Becker, GJ | 1 |
| Suzuki, H | 3 |
| Fujii, Y | 1 |
| Ito, M | 1 |
| Yoshida, Y | 1 |
| Inoshita, A | 1 |
| Baba, S | 1 |
| Takashima, H | 1 |
| Matavelli, LC | 1 |
| Siragy, HM | 2 |
| Wu, H | 1 |
| Chen, L | 1 |
| Peng, W | 1 |
| Xiang, A | 1 |
| Tang, R | 1 |
| Zhang, W | 1 |
| Abbott, KC | 1 |
| Bakris, GL | 1 |
| Taniwaki, H | 1 |
| Ishimura, E | 1 |
| Kawagishi, T | 1 |
| Matsumoto, N | 1 |
| Hosoi, M | 1 |
| Emoto, M | 1 |
| Shoji, T | 1 |
| Shoji, S | 1 |
| Nakatani, T | 1 |
| Inaba, M | 1 |
| Nishizawa, Y | 1 |
| Sato, A | 1 |
| Hayashi, K | 1 |
| Naruse, M | 1 |
| Saruta, T | 2 |
| McFarlane, SI | 1 |
| Sowers, JR | 1 |
| HANADA, M | 1 |
| CORBEL, L | 1 |
| Greminger, P | 1 |
| Mogensen, CE | 1 |
| Cooper, ME | 2 |
| Ambroisine, ML | 1 |
| Milliez, P | 1 |
| Nehme, J | 1 |
| Pasquier, AL | 1 |
| De Angelis, N | 1 |
| Mansier, P | 1 |
| Swynghedauw, B | 1 |
| Delcayre, C | 1 |
| Schjoedt, KJ | 4 |
| Andersen, S | 2 |
| Tarnow, L | 2 |
| Parving, HH | 6 |
| Halimi, JM | 1 |
| Jacobsen, P | 1 |
| Rossing, K | 3 |
| Boomsma, F | 3 |
| Jensen, BR | 1 |
| Han, SY | 2 |
| Jee, YH | 2 |
| Han, KH | 2 |
| Han, JY | 2 |
| Kim, YS | 2 |
| Matos, JP | 1 |
| de Lourdes Rodrigues, M | 1 |
| Ismerim, VL | 1 |
| Boasquevisque, EM | 1 |
| Genelhu, V | 1 |
| Francischetti, EA | 1 |
| Juhl, TR | 1 |
| Kalantarinia, K | 1 |
| Okusa, MD | 1 |
| Igarashi, M | 1 |
| Hirata, A | 1 |
| Kadomoto, Y | 1 |
| Tominaga, M | 1 |
| Epstein, M | 1 |
| Jandeleit-Dahm, K | 1 |
| Benck, U | 1 |
| Haeckel, S | 1 |
| Clorius, JH | 1 |
| van der Woude, FJ | 1 |
| Kelly, DJ | 1 |
| Zhang, Y | 1 |
| Moe, G | 1 |
| Naik, G | 1 |
| Gilbert, RE | 1 |
| O'Neill, H | 1 |
| Lebeck, J | 1 |
| Collins, PB | 1 |
| Kwon, TH | 1 |
| Frøkiaer, J | 1 |
| Nielsen, S | 1 |
| Yoneda, T | 1 |
| Takeda, Y | 1 |
| Usukura, M | 1 |
| Oda, N | 1 |
| Takata, H | 1 |
| Yamamoto, Y | 1 |
| Karashima, S | 1 |
| Yamagishi, M | 1 |
| Xue, C | 1 |
| Shamkhlova, MSh | 1 |
| Trubitsyna, NP | 1 |
| Katsaia, GV | 1 |
| Goncharov, NP | 1 |
| Malysheva, NM | 1 |
| Il'in, AV | 1 |
| Nikankina, LV | 1 |
| Koshel', LV | 1 |
| Shestakova, MV | 1 |
| Dai, WX | 1 |
| Tomita, K | 1 |
| Matsuda, O | 1 |
| Ideura, T | 1 |
| Shiigai, T | 1 |
| Takeuchi, J | 1 |
| Sugiyama, H | 1 |
| Uchimura, I | 1 |
| Odakura, T | 1 |
| Maezawa, H | 1 |
| Bannister, KM | 1 |
| Barratt, LJ | 1 |
| Kokot, F | 3 |
| Bodziony, D | 1 |
| Gómez-Martino, JR | 1 |
| Miralles, JM | 1 |
| De Leon, B | 1 |
| Hernandez, MT | 1 |
| Tabernero, JM | 1 |
| Jones, JW | 1 |
| Gruessner, RW | 1 |
| Gores, PF | 1 |
| Matas, AJ | 1 |
| Nørgaard, K | 1 |
| Rasmussen, E | 1 |
| Jensen, T | 1 |
| Giese, J | 3 |
| Feldt-Rasmussen, B | 2 |
| Strojek, K | 1 |
| Grzeszczak, W | 2 |
| Lacka, B | 1 |
| Górska, J | 1 |
| Morawin, E | 1 |
| Krywult, D | 1 |
| Mühlhauser, I | 1 |
| Prange, K | 1 |
| Sawicki, PT | 1 |
| Bender, R | 1 |
| Dworschak, A | 1 |
| Schaden, W | 1 |
| Berger, M | 1 |
| Sackmann, H | 1 |
| Tran-Van, T | 1 |
| Tack, I | 1 |
| Hanaire-Broutin, H | 1 |
| Tauber, JP | 1 |
| Ader, JL | 1 |
| Levine, DZ | 1 |
| Iacovitti, M | 1 |
| Burns, KD | 1 |
| Scherzer, P | 1 |
| Popovtzer, MM | 1 |
| Sparagana, M | 1 |
| Stone, WJ | 1 |
| Christlieb, AR | 2 |
| Kaldany, A | 1 |
| D'Elia, JA | 1 |
| Williams, GH | 1 |
| Fukuchi, S | 1 |
| Sasamura, H | 1 |
| Takita, T | 1 |
| Hayashi, M | 1 |
| Ohno, J | 1 |
| Shirai, T | 1 |
| Rosenberg, ME | 1 |
| Swanson, JE | 1 |
| Thomas, BL | 1 |
| Hostetter, TH | 1 |
| Hommel, E | 1 |
| Mathiesen, ER | 2 |
| Nielsen, MD | 2 |
| Schütten, HJ | 1 |
| O'Hare, JP | 1 |
| Anderson, JV | 1 |
| Millar, ND | 1 |
| Bloom, SR | 1 |
| Corrall, RJ | 1 |
| Yaginuma, K | 1 |
| Kusaka-Nakamura, M | 1 |
| Kishi, K | 1 |
| Miyazawa, A | 1 |
| Yagi, S | 1 |
| Sokabe, H | 1 |
| Duława, J | 1 |
| Wiecek, A | 1 |
| Baba, T | 1 |
| Murabayashi, S | 1 |
| Ishizaki, T | 1 |
| Ido, Y | 1 |
| Aoyagi, K | 1 |
| Takebe, K | 1 |
| Escarce, JJ | 1 |
| Deckert, T | 1 |
| Christensen, NJ | 1 |
| Bent-Hansen, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Improving Outcomes in Diabetic Nephropathy[NCT00381134] | Phase 2 | 92 participants (Anticipated) | Interventional | 2003-07-31 | Completed | ||
| Assessment of the Renin-angiotensin-aldosterone System (RAAS) and Antidiuretic Function in Patients With Type 2 Diabetes Before and During Treatment With Sodium-glucose Co-transporter 2 Inhibitors (SGLT2i): the GliRACo 1 Study[NCT03917758] | 30 participants (Anticipated) | Interventional | 2018-10-10 | Recruiting | |||
| Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria[NCT00320879] | Phase 4 | 52 participants | Interventional | 2003-09-30 | Completed | ||
| Spironolactone in Diabetic Nephropathy[NCT00317954] | Phase 4 | 48 participants | Interventional | 2003-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
26 reviews available for aldosterone and Diabetic Nephropathies
| Article | Year |
|---|---|
Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Clinical Relevance; Diabetes Mellitus; Diabetic Nephr | 2023 |
Mitigating risk of aldosterone in diabetic kidney disease.
Topics: Aldosterone; Cytochrome P-450 CYP11B2; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hy | 2020 |
Mineralocorticoid Antagonism and Diabetic Kidney Disease.
Topics: Adult; Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; | 2019 |
[Antifibrotic renal role of mineralcorticoid receptor antagonists].
Topics: Aldosterone; Body Fluids; Cardiovascular Diseases; Clinical Trials as Topic; Cytokines; Diabetic Nep | 2019 |
Aldosterone in vascular and metabolic dysfunction.
Topics: Adipocytes; Aldosterone; Animals; Blood Glucose; Blood Pressure; Coronary Circulation; Diabetic Neph | 2016 |
The novel mineralocorticoid receptor antagonist finerenone in diabetic kidney disease: Progress and challenges.
Topics: Aldosterone; Diabetic Nephropathies; Drug Therapy, Combination; Humans; Mineralocorticoid Receptor A | 2016 |
Impact of the renin-angiotensin-aldosterone-system on cardiovascular and renal complications in diabetes mellitus.
Topics: Aldosterone; Angiotensin II; Animals; Cardiovascular Diseases; Chymases; Diabetes Mellitus, Type 2; | 2010 |
Aldosterone blockade in diabetic nephropathy: relative risks and potential promise.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Diabetic Nephropathies; Humans; Lisinopril; M | 2009 |
Aldosterone and diabetic kidney disease.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Di | 2009 |
Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
Topics: Aldosterone; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibito | 2009 |
Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease.
Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Benzimidazoles; Be | 2010 |
Endocrinological aspects of proteinuria and podocytopathy in diabetes: role of the aldosterone/mineralocorticoid receptor system.
Topics: Aldosterone; Animals; Diabetic Nephropathies; Endocrinology; Humans; Models, Biological; Podocytes; | 2011 |
Renal protection in diabetes.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood Press | 2011 |
Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease.
Topics: Aldosterone; Animals; Chronic Disease; Cyclosporine; Diabetic Nephropathies; Humans; Kidney Diseases | 2011 |
Limitations of angiotensin inhibition.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2011 |
Treatment of the diabetic patient: focus on cardiovascular and renal risk reduction.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Aquaporins; Cardiovascular System; Diabetes M | 2002 |
Cardiovascular endocrinology 1: aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease.
Topics: Aldosterone; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Humans; Renin | 2003 |
[Rational diagnostic approach in hypertension].
Topics: Adrenal Gland Neoplasms; Aldosterone; Angiography; Cushing Syndrome; Diabetic Nephropathies; Diagnos | 2003 |
Diabetic renal disease: from recent studies to improved clinical practice.
Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood G | 2004 |
Aldosterone and anti-aldosterone effects in cardiovascular diseases and diabetic nephropathy.
Topics: Aldosterone; Cardiovascular Diseases; Diabetic Nephropathies; Humans; Mineralocorticoid Receptor Ant | 2004 |
Angiotensin II receptor blockade in diabetic nephropathy.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2004 |
The renin-angiotensin system and its blockade in diabetic renal and cardiovascular disease.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascu | 2006 |
Hypertension and diabetes: role of the renin-angiotensin system.
Topics: Aldosterone; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Complications; Diabetes Mell | 2006 |
[New findings with RAS inhibitors in diabetic nephropathy].
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Clin | 2007 |
Blockade of the renin-angiotensin-aldosterone system and renal protection in diabetes mellitus.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Diabetic Nephropathies; Humans; Randomized Co | 2000 |
[The renin-angiotensin-aldosterone system in diabetics].
Topics: Aldosterone; Angiotensin II; Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetic N | 1978 |
25 trials available for aldosterone and Diabetic Nephropathies
| Article | Year |
|---|---|
The renoprotective effect of esaxerenone independent of blood pressure lowering: a post hoc mediation analysis of the ESAX-DN trial.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2023 |
Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy.
Topics: Aged; Aldosterone; Angiotensin Receptor Antagonists; Diabetes Mellitus, Type 2; Diabetic Nephropathi | 2013 |
25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system.
Topics: Aged; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors | 2013 |
Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.
Topics: Adult; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitor | 2014 |
Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial.
Topics: Adult; Aged; Albuminuria; Aldosterone; Asian People; Blood Pressure; Diabetes Mellitus, Type 2; Diab | 2015 |
Albuminuria is associated with an increased prostasin in urine while aldosterone has no direct effect on urine and kidney tissue abundance of prostasin.
Topics: Adult; Aged; Albuminuria; Aldosterone; Animals; Antihypertensive Agents; Diabetic Nephropathies; Fem | 2017 |
Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Aldosterone; Amlodipine; Arteries; Calcium Channel Blockers; Calc | 2009 |
Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria.
Topics: Aged; Albuminuria; Aldosterone; Amlodipine; Angiotensin Receptor Antagonists; Blood Pressure; Calciu | 2011 |
Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
Topics: Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Acid; B | 2011 |
Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy.
Topics: Aldosterone; Amides; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fem | 2012 |
Additive renoprotective effects of aliskiren on angiotensin receptor blocker and calcium channel blocker treatments for type 2 diabetic patients with albuminuria.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Aged; Albuminuria; Aldosterone; Amides; Amlodipine; Angiotensin | 2012 |
Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease.
Topics: Aged; Albuminuria; Aldosterone; Amides; Antihypertensive Agents; Biomarkers; Blood Pressure; Diabeti | 2013 |
Intrarenal hemodynamic changes after captopril test in patients with type 2 diabetes: a duplex Doppler sonography study.
Topics: Adult; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Diabetes Me | 2003 |
Effectiveness of aldosterone blockade in patients with diabetic nephropathy.
Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Creatinine; Diab | 2003 |
Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate.
Topics: Adult; Albuminuria; Aldosterone; Antihypertensive Agents; Blood Pressure; Creatinine; Diabetes Melli | 2004 |
Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
Topics: Adult; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitor | 2005 |
Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria.
Topics: Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood P | 2005 |
Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conve | 2005 |
Beneficial impact of spironolactone in diabetic nephropathy.
Topics: Adult; Aldosterone; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Female; H | 2005 |
Dual blockade of angiotensin II with enalapril and losartan reduces proteinuria in hypertensive patients with type 2 diabetes.
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 2006 |
Proteinuria-lowering effect of heparin therapy in diabetic nephropathy without affecting the renin-angiotensin-aldosterone system.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Diabetic Nephropathies; Enoxaparin; Female; Fibrinolytic A | 2007 |
Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus.
Topics: Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Co | 2007 |
[Activity of the renin-angiotensin-aldosterone system in euglycemic type I diabetic patients on intensive insulin treatment without diabetic neuropathy].
Topics: Adult; Albuminuria; Aldosterone; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Humans; Insulin; | 1995 |
Effects of dietary sodium on blood pressure in IDDM patients with nephropathy.
Topics: Adolescent; Adult; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Blood Pressure; Blood Vol | 1996 |
Glomerular and hormonal responses to dietary protein intake in human renal disease.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aldosterone; Blood Proteins; Dextrans; Diabetic Nephropathies; | 1987 |
66 other studies available for aldosterone and Diabetic Nephropathies
| Article | Year |
|---|---|
Aldosterone-to-Renin Ratio Is Associated with Diabetic Nephropathy in Type 2 Diabetic Patients: A Single-Center Retrospective Study.
Topics: Adult; Aldosterone; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Male; Middle | 2022 |
Increased glucocorticoid metabolism in diabetic kidney disease.
Topics: Aldosterone; Diabetes Mellitus; Diabetic Nephropathies; Endothelial Cells; Female; Fibrosis; Glucoco | 2022 |
Mineralocorticoid interaction with glycated albumin downregulates NRF - 2 signaling pathway in renal cells: Insights into diabetic nephropathy.
Topics: Aldehyde Reductase; Aldosterone; Antioxidants; Catalase; Diabetic Nephropathies; Glutathione; Glutat | 2022 |
A case of idiopathic nodular glomerulosclerosis successfully treated by intensive blockade of the renin-angiotensin-aldosterone system.
Topics: Aged; Aldosterone; Angiotensins; Arteriosclerosis; Diabetic Nephropathies; Female; Humans; Proteinur | 2023 |
Sacubitril/valsartan ameliorates renal tubulointerstitial injury through increasing renal plasma flow in a mouse model of type 2 diabetes with aldosterone excess.
Topics: Aldosterone; Animals; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fibrosi | 2023 |
miR-196b-5p-enriched extracellular vesicles from tubular epithelial cells mediated aldosterone-induced renal fibrosis in mice with diabetes.
Topics: Aldosterone; Animals; Diabetes Mellitus; Diabetic Nephropathies; Epithelial Cells; Extracellular Ves | 2020 |
Amelioration of risk factors associated with diabetic nephropathy in diet-induced pre-diabetic rats by an uracil-derived diimine ruthenium(II) compound.
Topics: Albuminuria; Aldosterone; Animals; Biomarkers; Cell Adhesion Molecules; Creatinine; Diabetic Nephrop | 2020 |
The cytochrome 11B2 aldosterone synthase gene rs1799998 single nucleotide polymorphism determines elevated aldosterone, higher blood pressure, and reduced glomerular filtration, especially in diabetic female patients.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Case-Control Studies; Cytochrome P-450 CYP11B2; Diabetes M | 2020 |
Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes.
Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme 2; Animals; Autophagy; Beclin-1; Diabetes Me | 2019 |
Aldosterone breakthrough during angiotensin receptor blocker use: more questions than answers?
Topics: Aldosterone; Angiotensin Receptor Antagonists; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fe | 2013 |
Hemin therapy improves kidney function in male streptozotocin-induced diabetic rats: role of the heme oxygenase/atrial natriuretic peptide/adiponectin axis.
Topics: Adiponectin; Aldosterone; Animals; Atrial Natriuretic Factor; Cytokines; Diabetes Mellitus, Experime | 2014 |
Plasma soluble (pro)renin receptor is independent of plasma renin, prorenin, and aldosterone concentrations but is affected by ethnicity.
Topics: Adolescent; Adult; Aged; Aldosterone; Black People; Diabetes Mellitus, Type 1; Diabetes Mellitus, Ty | 2014 |
Renin-angiotensin-aldosterone-blockade is associated with decreased use of antidepressant therapy in patients with type 1 diabetes and diabetic nephropathy.
Topics: Adult; Aged; Aldosterone; Angiotensins; Antidepressive Agents; Antihypertensive Agents; Cross-Sectio | 2014 |
Urinary angiotensin-converting enzyme 2 increases in diabetic nephropathy by angiotensin II type 1 receptor blocker olmesartan.
Topics: Aged; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Blood P | 2015 |
Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
Topics: Aldosterone; Animals; Benzhydryl Compounds; Chymosin; Diabetes Mellitus, Type 2; Diabetic Nephropath | 2016 |
Increased aldosterone levels in a model of type 2 diabetes mellitus.
Topics: Actins; Albuminuria; Aldosterone; Animals; Blood Pressure; Cytochrome P-450 CYP11B2; Diabetes Mellit | 2009 |
Polymorphism of the aldosterone synthase gene is not associated with progression of diabetic nephropathy, but associated with hypertension in type 2 diabetic patients.
Topics: Adult; Aged; Aldosterone; Cytochrome P-450 CYP11B2; Diabetes Mellitus, Type 2; Diabetic Nephropathie | 2008 |
SGK1-sensitive renal tubular glucose reabsorption in diabetes.
Topics: Absorption; Age Factors; Aldosterone; Animals; Biological Transport; Blood Glucose; Body Weight; Cre | 2009 |
Adenosine A(1) receptors determine glomerular hyperfiltration and the salt paradox in early streptozotocin diabetes mellitus.
Topics: Aldosterone; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Nephropa | 2009 |
Association of (pro)renin receptor mRNA expression with angiotensin-converting enzyme mRNA expression in human artery.
Topics: Aged; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors | 2009 |
eNOS knockout mice with advanced diabetic nephropathy have less benefit from renin-angiotensin blockade than from aldosterone receptor antagonists.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Diabetes | 2010 |
Diabetic nephropathy: Aldosterone breakthrough in patients on an ACEI.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Diabetic Nephropathies; Humans | 2010 |
[Effect of aldosterone and its antagonist spironolactone on epithelial-mesenchymal transition of normal rat kidney epithelial cells in high glucose].
Topics: Aldosterone; Animals; Cell Differentiation; Cell Line; Cells, Cultured; Diabetic Nephropathies; Epit | 2010 |
Inhibition of the renal renin-angiotensin system and renoprotection by pitavastatin in type1 diabetes.
Topics: Aldosterone; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropat | 2010 |
Effect of atorvastatin on aldosterone production induced by glucose, LDL or angiotensin II in human renal mesangial cells.
Topics: Aldosterone; Angiotensin II; Anticholesteremic Agents; Atorvastatin; Cytochrome P-450 CYP11B2; Diabe | 2010 |
Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects?
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2010 |
[Aldosterone exacerbates chronic renal insufficiency].
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anim | 2011 |
Long-term mineralocorticoid receptor blockade ameliorates progression of experimental diabetic renal disease.
Topics: Aldosterone; Animals; Blood Pressure; Blotting, Western; Collagen Type IV; Diabetes Mellitus, Experi | 2012 |
Reduction of aldosterone production improves renal oxidative stress and fibrosis in diabetic rats.
Topics: Aldosterone; Amides; Amlodipine; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Cy | 2013 |
Spironolactone rescues Dot1a-Af9-mediated repression of endothelin-1 and improves kidney injury in streptozotocin-induced diabetic rats.
Topics: Acute Kidney Injury; Aldosterone; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; | 2012 |
[ALDOSTERONE SECRETION RATE IN VARIOUS DISEASES].
Topics: Aldosterone; Cushing Syndrome; Diabetic Nephropathies; Heart Diseases; Humans; Hyperaldosteronism; H | 1963 |
[FAMILIAL DIABETIC NEPHROPATHY IN A NEWBORN].
Topics: Aldosterone; Dehydration; Diabetic Nephropathies; Diagnosis; Humans; Infant; Infant, Newborn; Natriu | 1965 |
[The kidney and diabetes].
Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Diabetic Nephropa | 2004 |
Role of aldosterone in diabetic nephropathy.
Topics: Albuminuria; Aldosterone; Animals; Cells, Cultured; Chemokine CCL2; Collagen; Connective Tissue Grow | 2005 |
Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Aldosterone; Animals; Collagen Type IV; Connective Tissue Gro | 2006 |
Adding spironolactone to conventional antihypertensives reduces albuminuria in patients with diabetic nephropathy.
Topics: Adult; Aldosterone; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Female; H | 2006 |
Renin Academy hosts Topical Workshop session at ESH 2006.
Topics: Aldosterone; Diabetic Angiopathies; Diabetic Nephropathies; Humans; Renin; Renin-Angiotensin System | 2006 |
Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats.
Topics: Aldosterone; Amides; Animals; Body Weight; Diabetes Mellitus, Experimental; Diabetic Nephropathies; | 2007 |
Aldosterone-mediated apical targeting of ENaC subunits is blunted in rats with streptozotocin-induced diabetes mellitus.
Topics: Aldosterone; Animals; Aquaporin 2; Aquaporin 3; Arginine Vasopressin; Diabetes Mellitus, Experimenta | 2008 |
Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats.
Topics: Adrenalectomy; Albuminuria; Aldosterone; Animals; Blood Glucose; Collagen Type IV; Cytochrome P-450 | 2008 |
[The angiotensin II inhibition escape phenomenon in patients with type 2 diabetes and diabetic nephropathy].
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Di | 2008 |
[Plasma renin activity and plasma aldosterone change in diabetic nephropathy].
Topics: Adult; Aldosterone; Diabetic Nephropathies; Female; Humans; Hypertension; Male; Middle Aged; Posture | 1983 |
Renin-angiotensin-aldosterone system in mild diabetic nephropathy.
Topics: Adolescent; Adrenal Glands; Adult; Aged; Aldosterone; Blood Vessels; Diabetes Mellitus; Diabetic Nep | 1982 |
Plasma renin and aldosterone in adult-onset diabetics with persistent proteinuria.
Topics: Aldosterone; Angiotensin II; Bed Rest; Diabetes Complications; Diabetes Mellitus; Diabetic Nephropat | 1981 |
Hyperkalemia in a diabetic due to renal tubular unresponsiveness to aldosterone.
Topics: Aldosterone; Diabetes Mellitus; Diabetic Nephropathies; Humans; Hydrocortisone; Hyperkalemia; Kidney | 1982 |
[A case for discussion: hyperkalemia in a 64-year old patient].
Topics: Aldosterone; Diabetic Nephropathies; Diagnosis, Differential; Female; Humans; Hyperkalemia; Kidney F | 1982 |
Urinary prostaglandins (PGE2 and PGI2) in hyporeninaemic hypoaldosteronism in diabetic patients with chronic renal failure.
Topics: Aldosterone; Creatinine; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Dinoprostone; Epoprosten | 1994 |
Hypoaldosteronemic hyporeninemic hyperkalemia after renal transplantation.
Topics: Adult; Aldosterone; Cyclosporine; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Drug Therapy, C | 1993 |
Nature of elevated blood pressure in normoalbuminuric type I diabetic patients. Essential hypertension?
Topics: Adolescent; Adult; Albuminuria; Aldosterone; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type | 1993 |
Renal functional reserve in IDDM patients.
Topics: Adult; Albuminuria; Aldosterone; Amino Acids; Blood Glucose; Blood Pressure; C-Peptide; Creatinine; | 1998 |
Distal tubule bicarbonate reabsorption in intact and remnant diabetic kidneys.
Topics: Absorption; Acid-Base Equilibrium; Acidosis; Aldosterone; Animals; Bicarbonates; Biological Transpor | 2000 |
Segmental localization of mRNAs encoding Na(+)-K(+)-ATPase alpha(1)- and beta(1)-subunits in diabetic rat kidneys using RT-PCR.
Topics: Aldosterone; Animals; Anti-Bacterial Agents; Blood Glucose; Blotting, Northern; Diabetes Mellitus, E | 2002 |
Hyporeninemic hypoaldosteronism with diabetic glomerulosclerosis.
Topics: Adrenocorticotropic Hormone; Adult; Aldosterone; Blood Glucose; Blood Urea Nitrogen; Carbon Dioxide; | 1975 |
Grand rounds: Nashville VA Hospital--Vanderbilt University. Saturday conference: renal disease in the juvenile diabetic.
Topics: Acute Kidney Injury; Aldosterone; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Humans; Insulin | 1979 |
Aldosterone responsiveness in patients with diabetes mellitus.
Topics: Aldosterone; Diabetes Complications; Diabetes Mellitus; Diabetic Nephropathies; Electrolytes; Female | 1978 |
Renin-angiotensin-aldosterone system in diabetes mellitus.
Topics: Aldosterone; Angiotensin II; Animals; Blood Volume; Diabetes Mellitus; Diabetes Mellitus, Experiment | 1976 |
[Diabetes mellitus and its complications in Japan. Studies on the cause and treatment of hyporeninemic selective hypoaldosteronism in diabetic nephropathy].
Topics: Adrenergic beta-Antagonists; Aldosterone; Desoxycorticosterone; Diabetic Nephropathies; Diuretics; F | 1991 |
Response of plasma immunoreactive active renin, inactive renin, plasma renin activity, and aldosterone to hemodialysis in patients with diabetic nephropathy.
Topics: Adult; Aldosterone; Cold Temperature; Diabetic Nephropathies; Enzyme Precursors; Humans; Male; Renal | 1990 |
On the pathogenesis of arterial blood pressure elevation early in the course of diabetic nephropathy.
Topics: Adult; Aldosterone; Angiotensin I; Angiotensin II; Atrial Natriuretic Factor; Diabetes Mellitus, Typ | 1989 |
The relationship of the renin-angiotensin-aldosterone system to atrial natriuretic peptide and the natriuresis of volume expansion in diabetics with and without proteinuria.
Topics: Adult; Aldosterone; Atrial Natriuretic Factor; Blood Volume; Diabetes Mellitus; Diabetic Nephropathi | 1988 |
[Studies on hypoaldosteronism associated with diabetes mellitus: response of plasma steroids to angiotensin II or ACTH administration].
Topics: 18-Hydroxycorticosterone; Adrenocorticotropic Hormone; Adult; Aged; Aldosterone; Angiotensin II; Cor | 1986 |
Antihypertensive treatment in spontaneously hypertensive rats with streptozotocin-induced diabetes mellitus.
Topics: Aldosterone; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Creatinine; Diabetes M | 1988 |
[Effect of water immersion on plasma renin activity, vasopressin and aldosterone level in diabetics].
Topics: Aldosterone; Arginine Vasopressin; Blood Volume; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type | 1987 |
Renal kallikrein in diabetic patients with hypertension accompanied by nephropathy.
Topics: Adult; Aged; Aldosterone; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; | 1986 |
Hyporeninemic hypoaldosteronism in a patient with cirrhosis and ascites.
Topics: Aldosterone; Ascites; Diabetic Nephropathies; Female; Humans; Liver Cirrhosis; Middle Aged; Renin | 1986 |
Central role for sodium in the pathogenesis of blood pressure changes independent of angiotensin, aldosterone and catecholamines in type 1 (insulin-dependent) diabetes mellitus.
Topics: Adolescent; Adult; Aldosterone; Angiotensin II; Blood Pressure; Blood Volume; Diabetes Mellitus, Typ | 1987 |